多発性硬化症の市場規模、シェア、成長分析：薬剤クラス別、診断別、投与経路別、流通チャネル別、エンドユーザー別、地域別 - 産業予測 2025年～2032年

多発性硬化症の世界市場規模は、2023年に260億4,000万米ドルと評価され、2024年の266億4,000万米ドルから2032年には319億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは2.3％で成長する見通しです。

多発性硬化症（MS）治療市場は、有病率の増加と研究開発への注力の高まりにより、大きな成長が見込まれています。MSは、中枢神経系の免疫介在性障害を特徴とし、疲労、しびれ、認知障害などの症状を引き起こします。モノクローナル抗体は治療において極めて重要な役割を担っており、革新的な治療法の開発を目指した臨床試験が進行中です。ヒト化モノクローナル抗体と免疫抑制剤の需要は、MSの効果的な管理に対する緊急性を反映して、世界的に急増しています。製薬会社と学術機関との共同研究契約は市場活動をさらに活発化させ、MS治療薬開発をヘルスケア分野における投資と技術革新の主要分野として位置づけています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

多発性硬化症市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 免疫調節薬
• 免疫抑制剤
• インターフェロン
• その他

多発性硬化症市場規模：診断別& CAGR（2025-2032）

• 市場概要
• 磁気共鳴画像（MRI）
• 簡単な電気刺激テスト
• 腰椎穿刺
• その他

多発性硬化症市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 非経口
• その他

多発性硬化症市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

多発性硬化症市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 専門クリニック
• ホームケア
• その他

多発性硬化症市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Biogen Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Key Developments
• Merck KGaA（Germany）
• Bayer AG（Germany）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• TG Therapeutics, Inc.（United States）
• Acorda Therapeutics, Inc.（United States）
• Alkermes plc（Ireland）
• H. Lundbeck A/S（Denmark）
• Eli Lilly and Company（United States）
• GlaxoSmithKline plc（United Kingdom）
• Pfizer Inc.（United States）
• Celgene Corporation（United States）
• Mallinckrodt Pharmaceuticals（United Kingdom）
• UCB S.A.（Belgium）
• Orion Corporation（Finland）

結論と推奨事項

Global Multiple Sclerosis Market size was valued at USD 26.04 billion in 2023 and is poised to grow from USD 26.64 billion in 2024 to USD 31.95 billion by 2032, growing at a CAGR of 2.3% during the forecast period (2025-2032).

The market for multiple sclerosis (MS) treatments is poised for significant growth, driven by the increasing prevalence of the disease and a heightened focus on research and development. MS, characterized by immune-mediated damage to the central nervous system, leads to symptoms like fatigue, numbness, and cognitive issues. Monoclonal antibodies play a pivotal role in treatment, with ongoing clinical trials aimed at developing innovative therapies. The demand for humanized monoclonal antibodies and immunosuppressive drugs is surging globally, reflecting the urgency for effective MS management. Collaborative research agreements between pharmaceutical companies and academic institutions have further intensified market activity, positioning MS medication development as a key area of investment and innovation in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Market Segments Analysis

Global Multiple Sclerosis Market is segmented by Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users and Region. Based on Drug Class, the market is segmented into Immunomodulators, Immunosuppressants, Interferons and Others. Based on Diagnosis, the market is segmented into Magnetic Resonance Imaging (MRI), Simple Electrical Stimulation Tests, Lumbar Puncture and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Multiple Sclerosis Market

The rising prevalence of multiple sclerosis is a key factor fueling the growth of the global market. This condition is divided into four distinct types: relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS). The high incidence rates associated with these forms are likely to significantly influence market trends and dynamics throughout the forecast period. As more individuals are diagnosed and require effective treatments, the demand for innovative therapies and medical solutions is expected to increase, ultimately driving the overall expansion of the multiple sclerosis market on a global scale.

Restraints in the Global Multiple Sclerosis Market

Conversely, the Global Multiple Sclerosis market is likely to experience constraints that could hinder its growth. The exorbitant expense associated with the treatment of multiple sclerosis poses a significant barrier to market expansion. Additionally, developing countries are grappling with a shortage of trained professionals and insufficient healthcare infrastructure, further complicating access to treatment. The COVID-19 pandemic has also led to a decline in clinical visits, and a general lack of awareness among the public regarding the disease can impede market progress. These factors collectively are expected to restrain the market's growth throughout the forecast period from 2022 to 2029.

Market Trends of the Global Multiple Sclerosis Market

The global Multiple Sclerosis (MS) market is witnessing a robust trend driven by significant investments in research and development (R&D) aimed at innovative treatments. Pharmaceutical companies, including emerging players like Pipeline Therapeutics, are increasingly focusing on advanced therapeutic candidates, such as PIPE-307, a selective M1 receptor antagonist currently undergoing clinical trials. The proliferation of research collaborations between pharmaceutical firms and academic institutions further enhances the landscape, spurring growth. As companies diversify their pipelines with novel treatment options, this renewed emphasis on R&D is poised to catalyze market expansion, providing patients with more effective treatment choices and improving overall outcomes in MS management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Multiple Sclerosis Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulators
• Immunosuppressants
• Interferons
• Others

Global Multiple Sclerosis Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Magnetic Resonance Imaging (MRI)
• Simple Electrical Stimulation Tests
• Lumbar Puncture
• Others

Global Multiple Sclerosis Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Multiple Sclerosis Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Multiple Sclerosis Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Multiple Sclerosis Market Size & CAGR (2025-2032)

• North America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • US
  • Canada
• Europe (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Diagnosis, Route of Administration, Distribution Channel, End-Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
• Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TG Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations